- Previous Close
0.2560 - Open
0.2940 - Bid 0.2580 x 500000
- Ask 0.2900 x 500000
- Day's Range
0.2920 - 0.2940 - 52 Week Range
0.2100 - 0.6300 - Volume
4,418 - Avg. Volume
10,539 - Market Cap (intraday)
384.853M - Beta (5Y Monthly) -0.56
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date Mar 3, 2025 - Mar 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
www.nwbio.comRecent News: NBYB.SG
View MorePerformance Overview: NBYB.SG
Trailing total returns as of 1/3/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NBYB.SG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NBYB.SG
View MoreValuation Measures
Market Cap
349.36M
Enterprise Value
402.88M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
200.06
Price/Book (mrq)
--
Enterprise Value/Revenue
261.29
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-137.16%
Return on Equity (ttm)
--
Revenue (ttm)
1.65M
Net Income Avi to Common (ttm)
-75.55M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
2.88M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-37.45M